Skip to main content

Advertisement

SpringerLink
Log in

Comparative activity of ifosfamide and cyclophosphamide

  • International Satellite Symposium to the 3rd European Conference on Clinical Oncology Stockholm, June 1985 Recent Experience with Ifosfamide/Mesna in Solid Tumor
  • Ifosfamide, Cyclophosphamide
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Antitumor activity (increase in lifespan and cure) was greater for ifosfamide (IFO) in several experimental tumors, some of which were primarily resistant to cyclophosphamide (CYC).

IFO has been shown to be active in anthracycline-resistant and in adriamycin/cisplatin-resistant sublines of an Ehrlich ascites tumor, as well as in tumor cells primarily resistant to CYC. The few comparative controlled clinical trials available suggest superior single-agent activity of IFO compared with CYC in soft tissue sarcoma and ovarian cancer. Combination chemotherapy with IFO has been effective in second-line treatment of sarcomas, malignant lymphomas, lung cancer, and testicular cancer, most of them pretreated with or refractory to CYC.

Although it is difficult to obtain clinical proof that there is no cross-resistance between IFO and CYC, IFO has been shown to be active in multirefractory malignant lymphomas, in small cell lung cancer not responding to adriamycin, vincristine, and etoposide, and in soft tissue and bone sarcomas. Testicular cancer and pancreatic cancer are some of the tumors in which IFO activity is currently being evaluated and in which CYC has so far failed to show sufficient clinical activity.

More comparative controlled clinical trials are needed in ovarian cancer, breast cancer, malignant lymphomas, sarcomas and cervical cancer, in which IFO has already shown sufficient single-agent activity.

Due to its lower level of cross-resistance with a variety of heterocyclic products, but also with other alkylating agents, in addition to its use in induction chemotherapy, IFO is an important second-line agent in many clinical situations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abel HH (1977) Toxicological investigations of Ifosfamide. In: Burkert H, Voigt HC (eds) Proceedings of the International Holoxan Symposium, Düsseldorf. Asta-Werke, Bielefeld

    Google Scholar 

  2. Adiga KM (1981) Bladder tumour after treatment for lymphoma. Med J Aust 1: 190

    Google Scholar 

  3. Ahmann DL, Hahn RG, Bisel HF (1974) A phase II evaluation of ifosfamide (NSC 109 724) treatment of disseminated breast cancer. Proc Am Assoc Cancer Res 15: 1982 (Abstr 794)

    Google Scholar 

  4. Allen LM, Creaven PJ (1972) In vitro activation of ifosfamide (NSC-109724), a new oxazaphosphorine, by rat liver microsomes. Cancer Chemother Rep 56: 603

    Google Scholar 

  5. Anderson, T (1965) Cyclophosphamide. In: Fairly LG, Simister FJ (eds) Baltimore, p 92

  6. Ando K, Maruoka M, Hara S, Shimazaki (1981) Treatment of reactivated prostatic cancer with ifosfamide. Hishinohan Hinyokika—West Jpn J Urol 43: 1299

    Google Scholar 

  7. Ansell ID, Castro JE (1975) Carcinoma of the bladder complicating cyclophosphamide therapy. Br J Urol 47: 413

    Google Scholar 

  8. Ansher AF, Melton JW, Sliwinski AJ (1983) Bladder malignancy in a patient receiving low dose cyclophosphamide for treatment of rheumatoid arthritis. Arthritis Rheum 26: 804

    Google Scholar 

  9. Antman KH, Montella D, Rosenbaum Ch, Schwen M (1985) Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. Cancer Treat Rep 69: 499

    Google Scholar 

  10. Ardenne M v, Reitnauer PG, Rohde K (1971) Vergleich von Ifosfamid mit Cyclophosphamid bei der Therapie des DS-Karzinosarkoms der Ratte. Arch Geschwulstforsch 38: 15

    Google Scholar 

  11. Beck RE, Boyes DA (1968) Treatment of 126 cases of advanced ovarian carcinoma with cyclophosphamide. Can Med Assoc J 98: 539

    Google Scholar 

  12. Bethel FH, Louis J, Robbins A, Donelly WJ, Dessel BH, Battle JD, Pisciotta AV, Will J, Clifford GO (1960) Phase II evaluation of cyclophosphamide. Cancer Chemother Rep 8: 112

    Google Scholar 

  13. Beyer-Boom ME, de Voogt HJ, Schaberg A (1978) The effect of cyclophosphamide treatment on the epithelium and stroma of the urinary bladder. Eur J Cancer 14: 1029

    Google Scholar 

  14. Bischel MD (1979) Cyclophosphamide — Hemorrhagic cystitis following prolonged low-dose therapy. J A M A 242: 237

    Google Scholar 

  15. Blume B, Rabe F, Theuring F (1984) Urothelkarzinom der Harnblase nach Cyclophosphamid-Therapie. Z Urol Nephrol 77:7

    Google Scholar 

  16. Boutis LL, Stergiou-Tavantzis J, Mouratidou D, papadopoulou-Boutis A, Hatzigogos K, Bouhoris N, Dimitriadis K, Koukourikos S (1982) Ifosfamide chemotherapy of disseminated non-seminomatous testicular tumors. Proc 13th Int Cancer Congress, Seattle, p 181

  17. Brade WP, Herdrich K, Varini M (1985) Ifosfamide — pharmaocology, safety and therapeutic potential. Cancer Treat Rev 12: 1

    Google Scholar 

  18. Bramwell VHC, Mouridsen HT, Santoro A, Blackledge G, Somers R, Thomas D, Sylvester R, van Oosterom A (1986). Cyclophosphamide versus Ifosfamide. Preliminary report of a randomized phase II trial in adult soft tissue sarcomas. Cancer Chemother Pharmacol 18 (Suppl 2): S 13

  19. Brema F, et al. (1977) Clinical evaluation of ifosfamide in solid epithelial advanced tumors. Med Sci Clin Pharmacol Ther 5: 122

    Google Scholar 

  20. Brock N (1972) Pharmacological studies with ifosfamide, a new oxazaphosphorine compound. In: Semonsky M, Hejzlar M, Masak S (eds) Advances in antimicrobial and antineoplastic chemotherapy. Proc. of the 7th Intern. Congress of Chemotherapy, Prague. Urban and Schwarzenberg, Munich Berlin Vienna, pp. 759–761

    Google Scholar 

  21. Brock N (1977) Contribution to the pharmacology of ifosfamide. In: Burkert H, Voigt HC (eds) Proceedings of the International Holoxan Symposium, Düsseldorf. Asta-Werke, Bielefeld

    Google Scholar 

  22. Brock N (1979) The special position of ifosfamide in the series of cytostatically active oxazaphosphoriens. In: Fox BW (ed) Advances in medical oncology. Research and education, vol 5: Basis for cancer therapy I. Pergamon Press, Oxford, New York

    Google Scholar 

  23. Brock N (1983) The oxazaphosphorines. Cancer Treat Rev 10 [Suppl A]: 3

    Google Scholar 

  24. Brock N (1983) Oxazaphosphorine cytostatics: structure-activity relationship, selectivity and metabolism, regional detoxification. In: Reinhoudt, D.; Connors ST, Pinedo H, van de Poll K (eds) Structure-activity relationships of anti-tumor agents. Nijhoff, The Hague, Boston, London

    Google Scholar 

  25. Brock N, Habs M, Pohl J, Schmähl D, Stekar J (1982) Mesna (natrium-2-mercaptoethansulfanat). Prophylaxe der akuten urotoxischen Nebenwirkungen sowie der kanzerogenen Spätfolgen von Cyclophosphamid und Ifosfamid. Therapiewoche 32: 4975

    Google Scholar 

  26. Brock N, Schneider B (1980) Models and methods for the assessment of cumulation of drug effects. Arzneimittelforsch (Drug Res) 30: 1034–1040

    Google Scholar 

  27. Brock N, Stekar J, Pohl J (1979) Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide, and sufosfamide. Arzneimittelforsch 29: 659

    Google Scholar 

  28. Brock N (1980) Konzeption und Wirkungsmechanismus von Uromitexan (Mesna). Beiträge zur Onkologie 5. Karger Basel München Paris London New York Sydney, pp. 1–11

    Google Scholar 

  29. Brock N, Hilgard P, Pohl J, Ormstad K, Orrenius S (1984) Pharmacokinetics and mechanism of action of detoxifying low-molecularweight thiols. J Cancer Res Clin Oncol 108: 87

    Google Scholar 

  30. Brühl P, Günther U, Hoefer-Janker H, Hüls W, Scheef W, Vahlensieck W (1976) Results obtained with fractionated ifosfamide massive-dose treatment in generalized malignant tumours. Int J Clin Pharmacol 14: 29

    Google Scholar 

  31. Buckner, CD, Clift RA, Fefer A, Funk DD, Glucksberg H, Neiman PE (1974) High-dose cyclophosphamide (NSC-26271) for the treatment of metastatic testicular neoplasms. Cancer Chemother Rep 58: 709

    Google Scholar 

  32. Burkert H, Schnitker J, Fichtner E (1979) Verhütung der Harnwegstoxizität von Oxazaphosphorinen durch einen Uroprotektor. Berich über eine Feldstudie. Mnch Med Wochenschr 121: 760

    Google Scholar 

  33. Bus JS, Gibson JE (1973) Teratogenicity and neonatal toxicity of ifosfamide in mice. Proc Soc Exp Biol Med 143: 965

    Google Scholar 

  34. Carbone PP, Spurr C, Schneiderman M (1968) Management of patients with malignant lymphoma: a comparative study with cyclophosphamide and vinca alkaloids. Cancer Res 28: 811

    Google Scholar 

  35. Carney CN, Stevens PS, Fired FA, Mandell J (1982) Fibroplastic tumor of the urinary bladder after cyclophosphamide therapy. Arch Pathol Lab Med 106: 247

    Google Scholar 

  36. Carter SK, Livingston RB (1975) Cyclophosphamide in solid tumors. Cancer Treat Rep 2: 295

    Google Scholar 

  37. Carter SK, Wasserman TH (1975) The chemotherapy of urologic cancer. Cancer 36: 729

    Google Scholar 

  38. Chasko StB, Keuhnelian JG, Gutowski WT, Gray GF (1980) Spindle cell cancer of bladder during cyclophosphamide therapy for Wegener's granulomatosis. Am J Surg Pathol 4: 191

    Google Scholar 

  39. Chodak GW, Strauss FW, Schoenberg HW (1981) Simultaneous occurrence of transitional, squamous and adenocarcinoma of the bladder after 15 years of cyclophosphamide ingestion. J Urol 125: 424

    Google Scholar 

  40. Connors TA, Cox PJ, Farmer PR, Foster AB, Jarman M (1974) Some studies of the active intermediates formed in the microsomal metabolites of cyclophosphamide and ifosfamide. Biochem. Pharmacol 23:115

    Google Scholar 

  41. Cooper RM, Rhyne AL, Muss HB, Ferree C, Richards F, White DR et al (1981) A randomized comparative trial of chemotherapy and irradiation therapy for stage II breast cancer. Cancer 47: 2833

    Google Scholar 

  42. Costanzi JJ, Gagliano R, Loukas D, Panettiere FJ, Hokanson JA (1978) Ifosfamide in the treatment of recurrent or disseminated lung cancer. A phase II study of two dose schedules. Cancer 41: 1715

    Google Scholar 

  43. Costanzi JJ, Stephens R, O'Bryan R, Franks J (1982 a) Ifosfamide in the management of malignant melanoma: a Southwest Oncology Group Phase II study. Semin Oncol 9: 93

    Google Scholar 

  44. Costanzi JJ, Morgan LR, Hokanson J (1982 b) Ifosfamide in the treatment of extensive non-oat cell carcinoma of the lung. Semin Oncol 9 [Suppl 4]: 61

    Google Scholar 

  45. Creaven PJ et al (1974) Clinical pharmacology of isophosphamide. Clin Pharmacol Ther 16: 77

    Google Scholar 

  46. Czownicki Z, Utracka B (1982) Ifosfamide (Holoxan) single-agent therapy in soft tissue sarcomas: a clinical phase II study. Proc 13th Int Cancer Congress, Seattle, p 416, Abstr 2379

  47. Czownicki Z, Utracka-Hutka B (1977) Contribution to the treatment of malignant tumors with ifosfamide. In: Burkert H, Voigt HC (eds) Proceedings of the International Holoxan Symposium, Düsseldorf. Asta-Werke, Bielefeld, p 109

    Google Scholar 

  48. Dale GA, Smith RB (1974) Transitional cell carcinoma of the bladder associated with cyclophosphamide. J Urol 112: 603

    Google Scholar 

  49. Decker DG, Malkasian GD, Mussey E, Johnson CE (1967) Cyclophosphamide. Am J Obstet Gynecol 97: 656

    Google Scholar 

  50. De Kraker J, Voute PA, Stassen M (1981) Clinical experience with the combination endoxan mesna in pediatrics. Contrib Oncol 5: 99

    Google Scholar 

  51. Depierre A (1977) Clinical trial of ifosfamide on patients with disseminated melanoma. In: Burkert H, Voigt HC (eds) Proceedings of the International Holoxan Symposium, Düsseldorf. Asta-Werke, Bielefeld, p 154

    Google Scholar 

  52. Druckrey H (1963) Experimentelle Beiträge zum Dosis-Problem in der Krebs-Chemotherapie und zur Wirkungsweise von Endoxan. Dtsch Med Wochenschr 88: 651, 715

    Google Scholar 

  53. Druckrey H (1973) Krebs-experimentelle Ursachenforschung und Chemotherapie. Z Krebsgeschehen 5: 73

    Google Scholar 

  54. Druckrey H (1970) Theoretical use of chemotherapy in the treatment of carcinoma. J Kanser (Ankara) 1: 131

    Google Scholar 

  55. Dumas JP, Roulet B, Colombeau P, Loubet R (1984) Cancers urothéliaux sous Endoxan. J Urol (Paris) 90: 411

    Google Scholar 

  56. Durkee C, Bensom R (1980) Bladder cancer following administration of cyclophosphamide. Urology 16: 145

    Google Scholar 

  57. Elliott RW, Essenhigh DM, Morley AR (1982) Cyclophosphamide treatment of systemic lupus erythematosus: risk of bladder cancer exceeds benefit. Br Med J 284: 1160

    Google Scholar 

  58. Fairchild WV, Spence R, Solomon H, Gangai MD (1979) The incidence of bladder cancer after cyclophosphamide therapy. J Urol 122: 163

    Google Scholar 

  59. Falkson G, Falkson HC (1976) Further experience with ifosfamide. Cancer Treat Rep 60: 955

    Google Scholar 

  60. Finkelstein JZ, Hittle, RE, Hammond GD (1969) Evaluation of high-dose cyclophosphamide regimens in childhood tumors. Cancer 23: 1239

    Google Scholar 

  61. First D, Olshin S (1968) Treatment of metastatic carcinoma of the female breast with combination of hormones and other chemotherapy. Cancer Chemother Rep 52: 743

    Google Scholar 

  62. Friedmann MA, Carter SK (1972) The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol 4: 482

    Google Scholar 

  63. Friedman OM, Myles A, Colvin M (1979) Cyclophosphamide and related phosphoramide mustards. In: Rosowsky A (ed) Advances in cancer chemotherapy. Dekker, New York

    Google Scholar 

  64. Frondoza CG, Trivedi SM, Humphrey RL (1982) Development and characterization of a cyclophosphamide-resistant mouse plasmacytoma cell line. Cancer Treat Rep 66: 1535

    Google Scholar 

  65. Fuchs EF, Kay R, Poole R, Barry JM (1981) Uroepothelial carcinoma in association with cyclophosphamide ingestion. J Urol 126: 544

    Google Scholar 

  66. Gad-El-Mawla N (1977) Trials with ifosfamide in malignancy. In: Burkert H, Voigt HC (eds) Proceedings of the International Holoxan Symposium, Düsseldorf. Asta-Werke, Bielefeld, p 107

    Google Scholar 

  67. Gad-El-Mawla N, Ziegler JL (1981) Ifosfamide treatment of pancreatic cancer. Cancer Treat Rep 65: 357

    Google Scholar 

  68. Gandola L, Pozzi E, Tansini G (1978) Ifosfamide in the treatment of bronchogenic carcinoma. A preliminary trial. G Ital Chemioter 25: 41

    Google Scholar 

  69. Garvin DD, Ball TP (1981) Bladder malignancy in patients receiving cyclosphamide for benign disease. Urology 18: 80

    Google Scholar 

  70. Garza J de la, Cardenas J (1982) Ifosfamide (Holoxan, IFA) in the treatment of advanced ovarian carcinoma. Proc 13th Int Cancer Congress, Seattle, p 76, Abstr 428

  71. Gellman E, Kissane J, Frech R, Vietti T, McAlister W (1969) Cyclophosphamide cystitis. J Can Assoc Radiol 20: 99

    Google Scholar 

  72. Gerecke D (1977) Comparative study on the cytotoxic activity of ifosfamide and cyclophosphamide against T-lymphocytes outside the proliferation cycle. In: Burkert H, Voigt HC (eds) Proceedings of the International Holoxan Symposium, Düsseldorf. Asta-Werke, Bielefeld, p 58

    Google Scholar 

  73. Glucksman MA (1980) Bladder cancer after cyclophosphamide therapy. Urology 16: 553

    Google Scholar 

  74. Goldin A (1982) Ifosfamide in experimental tumor systems. Semin Oncol 9 [Suppl 1]: 14

    Google Scholar 

  75. Goldin A et al (1977) Preclinical investigations with Ifosfamide in relation to cyclophosphamide. In: Burkert H, Voigt HC (eds) Proceedings of the International Holoxan Symposium, Düsseldorf. Asta-Werke, Bielefeld, p 19

    Google Scholar 

  76. Greco C, Corsi A, Caputo M, Cavallari A, Calabresi F (1979) Cyclophosphamide and iphosphamide against Lewis lung carcinoma: evaluation of toxic and therapeutic effects. Tumori 65: 169

    Google Scholar 

  77. Habs MR, Schmähl D (1983) Prevention of urinary bladder tumors in cyclophosphamide treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2′-dithio-bis-ethane sulfonate (dimesna). Cancer 51: 606

    Google Scholar 

  78. Haddy TB, Nora AW (1967) Cyclophosphamide treatment for metastatic soft tissue sarcoma. Intermittent large doses in the treatment of children. Am J Dis Child 114: 301

    Google Scholar 

  79. Haggard ME (1967) Cyclophosphamide (NCS-26271) in the treatment of children with malignant neoplasms. Cancer Chemother Rep 51: 403

    Google Scholar 

  80. Hansen HH, Muggia MM, Saini N (1971) Cyclophosphamide and the urinary bladder. N Engl J Med 284: 1043

    Google Scholar 

  81. Hansen SE (1983) Carcinoma of the bladder in a patient treated with cyclophosphamide for rheumatoid arthritis. Scand J Rheumatol 12: 73

    Google Scholar 

  82. Havemann K, Gropp C, Gassel WD (1980) Treatment of small-cell bronchial carcinoma with two new chemotherapy combinations (AIO study BI + II). Paper presented at the 29th Congress of the Deutsche Gesellschaft für Lungenkrankheiten und Tuberkulose, Berlin, p 99

  83. Helin I, Okmian L (1973) Haemorrhagic cystitis complicating cyclophosphamide treatment in children. Acta Paediatr Scand 62: 497

    Google Scholar 

  84. Hilgard P, Herdrich K, Brade WP (1983) Ifosfamide —current aspects and perspectives. Cancer Treat Rev 10 [Suppl A]: 183

    Google Scholar 

  85. Hill DL, Laster WF Jr, Kirk MC, El Dareer S, Struck RF (1973) Metabolism of ifosfamide and production of a toxic ifosfamide metabolite. Cancer Res 33: 1016

    Google Scholar 

  86. Hilton J, Cohen D (1982) Role of aldehyde dehydrogenase in the response of L1210 cells to cyclophosphamide and 4-methylcyclophosphamide. Proc Am Assoc Cancer Res 23:169

    Google Scholar 

  87. Hoefer-Janker H, Scheef W, Günther U, Hüls W (1975) Erfahrungen mit der fraktionierten Ifosfamid-Stoßtherapie bei generalisierten malignen Tumoren. Med Welt 26: 972

    Google Scholar 

  88. Hohorst HJ (1977) The problem of specifity and selectivity ofN-(2-chloroethyl)-amidooxazaphosphorines. In: Burkert H, Voigt HC (eds.) Proceedings of the International Holoxan Symposium, Düsseldorf. Asta-Werke Bielefeld

    Google Scholar 

  89. Holcomb TM (1967) Cyclophosphamide (NSC-26271) in the treatment of acute leukemia in children. Cancer Chemother Rep 51: 389

    Google Scholar 

  90. Jehn U, Wilmanns W (1981) Internistische Therapie des malignen Melanoms. Münch Med Wochenschr 123: 1945

    Google Scholar 

  91. Johnson DE, Scott WW, Gibbsons RP, Prout GR, Schmidt JD, Chu TM, Gaeta J, Saroff J, Murphy GP (1977) National randomized study of chemotherapeutic agents in advanced prostatic carcinoma: a progress report. Cancer Treat Rep61: 317

    Google Scholar 

  92. Kaplan S, Malinverni R, Varini M, Cavalli F (1981) Prevention of genitourinary toxicity of ifosfamide with Na-2-mercaptoethanesulfonate (mesna). In: Contributions to oncology, vol 5. Karger, Basel, p 52

    Google Scholar 

  93. Kato Y, Tsujihashi H, Matsuura T, Kaneko S, Iguchi M, Akiyama T (1981) A case of bladder tumor seemed to be associated with cyclophosphamide. Hinyokika Kiyo 27: 1383

    Google Scholar 

  94. Klein HO, Cristian E, Coerper C, Klein PJ, Scheef W, Brock N (1978) Experimental and clinical investigation on the protective effect of 2-mercapto-aethan-sulfon acid (MAS) on kidneys and urinary bladder during high-dose therapy with ifosfamide (IF) and cyclophosphamide (CPA). Paper presented at the 4th Annual Meeting of the Medical Oncological Society. Springer, New York, p 18

    Google Scholar 

  95. Lemmel EM (1977) Action of ifosfamide on immunological reactions in the mouse. In: Burkert H, Voigt HC (eds) Proceedings of the International Holoxan Symposium, Düsseldorf. Asta-Werke, Bielefeld, p 75

    Google Scholar 

  96. Liendberg CF, Rausing A, Langeland P (1970) Cyclophosphamide hemorrhagic cystitis. Scand J Urol Nephrol 4: 183

    Google Scholar 

  97. Livingston RB, Carter SK (1970) Single agents in cancer chemotherapy. IFI Plenum, New York

    Google Scholar 

  98. Lowenberg B, Abels J, Schroder FH (1980) Mesnum and cyclophosphamide cystitis. Lancet 2: 1195

    Google Scholar 

  99. Magrath IT et al (1985) Treatment of recurrent sarcomas with ifosfamide (IF). Proc Annu Meet Am Soc Clin Oncol 21: abstr C-528

  100. Manoharan A (1984) Carcinoma of the urinary bladder in patients receiving cyclophosphamide. Aust N Z J Med 14: 507

    Google Scholar 

  101. Marcy R, Semont H, Prost R (1977 a) A comparative toxicological study in mice and rats of the antimitotic drug ifosfamide and cyclophosphamide: acute tests by parenteral and oral routes. ICRS Med Sci 5: 148

    Google Scholar 

  102. Marcy R, Semont H, Prost R (1977 b) Comparative leucotoxic effects of the two isomeric anticancer agents cyclophosphamide and ifosfamide. ICRS Med Sci 5: 427

    Google Scholar 

  103. Marti Ch, Kroner T, Cserhati M (1981) Ifosphamide in the treatment of refractory metastatic osteosarcoma. UICC Congress 1981, Lausanne, Abstr 05-0041

  104. Marti Ch et al (1985) High-dose ifosfamide in advanced osteosarcoma. Cancer Treat Rep 69: 115

    Google Scholar 

  105. Matthias JQ, Misiewicz JJ, Scott RB (1960) Cyclophosphamide in Hodgkin's disease and related disorders. Br Med J 2: 1837

    Google Scholar 

  106. Meiners L, Bastert G, Eichholz H et al (1981) Untersuchungen zur sekundären Cyclophosphamidresistenz beim menschlichen Mammakarzinom nach Xenotransplantation auf nu/nu-Mäuse. Arch Gynecol 232: 298

    Google Scholar 

  107. Millac P, Miller H (1969) Cyclophosphamide in multiple sclerosis. Lancet 1: 783

    Google Scholar 

  108. Moinuddin SM, Upton DW (1983) Urothelial carcinoma after cyclophosphamide therapy. J Urol 129: 143

    Google Scholar 

  109. Morgan LR (1977) Ifosfamide in advanced lung cancer — low dose, fractionated schedule. In: Burkert H, Voigt HC (eds) Proceedings of the International Holoxan Symposium, Düsseldorf. Asta-Werke, Bielefeld, p 138

    Google Scholar 

  110. Morgan LR, Posey LE, Rainey J, Bickers J, Ryan D, Vial R, Hull EW (1981) Ifosfamide: a weekly dose fractionated schedule in bronchogenic carcinoma. Cancer Treat Rep 65: 693

    Google Scholar 

  111. Moriyama Y, Koike T, Shibata A (1984) Hemorrhagic cystitis after conditioning for bone marrow transplantation and its prophylaxis. Jpn J Clin Oncol 14: 531 (1984)

    Google Scholar 

  112. Nelson RL, Creaven PJ, Cohen MH, Fossieck BE (1976) Phase I clinical trial of a 3-day divided dose schedule of ifosfamide (NSC 109724). Eur J Cancer 12: 195

    Google Scholar 

  113. Niederle N, Scheulen ME, Cremer M, Schütte J, Schmidt CG, Seeber S (1983) Ifosfamide in combination chemotherapy for sarcomas and testicular carcinomas. Cancer Treat Rev 10 [Suppl A]: 129

    Google Scholar 

  114. Norpoth K (1976) Studies of the metabolism of ifosfamide (NSC 109724) in man. Cancer Treat Rep 60: 437

    Google Scholar 

  115. Norpoth K, Müller G, Raidt H (1976) Isolierung und Charakterisierung zweier Hauptmetabolite von Ifosfamid aus Patienten-Urin. Arzneim Forsch 25: 1376

    Google Scholar 

  116. Ota K (1977) Clinical experiences and results of treatment with ifosfamide. In: Burkert H, Voigt HC (eds) Proceedings of the International Holoxan Symposium, Düsseldorf. Asta-Werke, Bielefeld, p 108

    Google Scholar 

  117. Otaguro K, Ueda K, Niijima T, Kawai H, Matsumoto K, Kawai T et al (1981) Clinical evaluation of Z4942 (ifosfamide) for malignant urological tumors (in Japanese). Hinyokika Kiyo (J Urol) 27: 459

    Google Scholar 

  118. Phelan ET, Vietti TJ, Valeriote FA, Coulter D (1981) Comparison of cytotoxic action of ifosfamide and cyclophosphamide. Anticancer Res 1: 149

    Google Scholar 

  119. Pierce M, Shore N, Sitarz A, Murphy ML, Louis, J, Severo N (1966) Cyclophosphamide therapy in acute leukemia of childhood. Cancer 19: 1551

    Google Scholar 

  120. Plotz PH, Klippel JH, Decker JL, Graumann D, Wolf B, Brown BC, Rutt G (1979) Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Ann Intern Med 91: 221

    Google Scholar 

  121. Posey LE, Morgan L, Carter RD, Sutherland C, Krementz ET & Bickers (1980) A comparison of cyclophosphamide and ifosfamide in advanced bronchogenic carcinoma. Proc Am Assoc Cancer Res 19: 338

    Google Scholar 

  122. Richtsmeier AJ (1975) Urinary-bladder tumors after cyclophosphamide. N Engl J Med 293: 1045

    Google Scholar 

  123. Ritzel S, Sulkes A, Gez E, Brufman G, Bivan S (1981) First, second and third line chemotherapy programs in metastatic breast carcinoma. Isr J Med Sci 17: 946

    Google Scholar 

  124. Rodriguez V, Cabanillas F, Bodey GP, Freireich EJ (1978) Isophosphamide therapy for hematologic malignancies in patients refractory to prior treatment. Cancer Treat Rep 62: 493

    Google Scholar 

  125. Röhrborn G, Basler A (1977) Cytogenetic investigations of mammals. Comparison of the genetic activity of cytostatics in mammals. Arch Toxicol 38: 35

    Google Scholar 

  126. Rosso R, Brema F, Nobile MT, Campora E (1982) Phase II study of ifosfamide plus uroprotective mesna in advanced solid tumors. Proc 13th Int Cancer Congress, Seattle. p 529, Abstr 3021

  127. Rupprecht L, Blessing MH (1973) Fibrosarkom der Harnblase nach siebenjähriger Chemotherapie einer Lymphogranulomatose im Kindesalter. Dtsch Med Wochenschr 98: 1663

    Google Scholar 

  128. Sampey JR (1967) Management of Hodgkin's disease and the leukemias with cytoxan II. Clinical reports 1960–62. Am J Pharm 134: 305

    Google Scholar 

  129. Samra Y, Hertz M, Lindner A (1985) Urinary bladder tumors following cyclophosphamide therapy: a report of two cases with a review of the literature. Med Pediatr Oncol 13: 86

    Google Scholar 

  130. Scheulen ME, Niederle N, Seeber S (1980) Ergebnisse einer klinischen Phase II-Studie von Ifosfamid bei therapiefraktären malignen Erkrankungen. Vergleich der uroprotektiven Wirkung von Uromitexan mit forcierter Diurese und Alkalisierung des Urins. In: Burkert H, Nagel GA (eds) Contributions to oncology, vol 5. Karger, Basel, p 40

    Google Scholar 

  131. Scheulen ME, Bremer K, Niederle N, Krischke W, Higi M, Seeber S, Schmidt CG (1981) Ifosfamide and etoposide in refractory testicular tumors. UICC Conference on Clinical Oncology, p 129, Abstr 15-0373

  132. Scheulen ME, Niederle N, Seeber S (1981) Results of a clinical phase II study on the use of ifosfamide in refractory malignant diseases. Comparison of the uroprotective effect of uromitexan and forced diuresis with alkalization of the urine. In: Burkert H, Nagel GA (eds) New experience with the oxazaphosphorines with special reference to the uroprotector uromitexan. Karger, Basel, p 41

    Google Scholar 

  133. Scheulen ME, Niederle N, Bremer K, Schütte J, Seeber S (1983) Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna. Results of a clinical phase II-study with 151 patients. Cancer Treat Rev 10 [Suppl A]: 93

    Google Scholar 

  134. Schiff HI, Finkel M, Schapira HE (1982) Transitional cell carcinoma of the ureter associated with cyclophosphamide therapy for benign disease: a case report. J Urol 128: 1023

    Google Scholar 

  135. Schmähl D, Habs MR (1983) Prevention of cyclophosphamide-induced carcinogenesis in the urinary bladder of rats by administration of mesna. Cancer Treat Rev 10 [Suppl]: 57

    Google Scholar 

  136. Schmitz G, Gross R (1967) Erste klinische Erfahrung mit ultrahohen Einzeldosen von Cyclophosphamid. Med. Welt 18: 985

    Google Scholar 

  137. Schmoll HJ (1982) The role of ifosfamide (IPP) in testicular cancer. Proc 13th Int Cancer Congress, Seattle, p 626, Abstr 3580

  138. Schneidegger S (1972) Lungenfibrose, rezidivierende Vaskulitis und multizentrisches Lungenkarzinom nach zytostatischer Therapie mit Alkeran. Verh Dtsch Ges Pathol 56: 364

    Google Scholar 

  139. Schnitker J, Brock N, Burkert H, Fichtner E (1976) Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide. Arzneimittelforsch (Drug Res) 26: 1783

    Google Scholar 

  140. Scott WW, Johnson DE, Schmidt JE, Gibbsons RP, Prout GR, Joiner JR, Saroff J, Murphy GP (1975) Chemotherapy of advanced prostatic carcinoma with cyclophosphamide or 5-fluorouracil: results of the first national randomized study. J Urol 114: 909

    Google Scholar 

  141. Seeber S, Niederle N, Osieka N, Osieka R, Schütte J (1984 a) Experimentelle und klinische Untersuchungen zur Wirksamkeit von Ifosfamid bei refraktären Neoplasien. Tumor Diagnostik u Therapie 5: 39

    Google Scholar 

  142. Seeber S, Dimitriadis K, Schütte J, Schmidt CG (1984b) Experimental basis and clinical experience with non-cross-resistant combinations in solid tumours. Cancer Treat Rev 11: 55 (Suppl A)

    Google Scholar 

  143. Seo IS, Clark SA, McGovern FD, Clark DL, Johnson EH (1985) Leyomyosarcoma of the urinary bladder. 13 years after cyclophosphamide therapy for Hodgkin's disease. Cancer 55: 1597

    Google Scholar 

  144. Sladek NE (1973) Bioassay and relative cytotoxic potency of cyclophosphamide metabolites generated in vitro and in vivo. Cancer Res 33: 1150

    Google Scholar 

  145. Spiers ASD (1963) Haemorrhagic cystitis and cyclophosphamide. Lancet 2: 1282

    Google Scholar 

  146. Stekar J (1976) Chemotherapeutische Wirksamkeit von Ifosfamid an 6 verschiedenen, isolog transplantierten Experimentaltumoren (BD-Ratten). Arzneimittelforsch (Drug Res) 26: 1793

    Google Scholar 

  147. Stuart-Harris RC, Harper PG, Parson CA, Kaye StB, Mooney CA, Gowing NF, Wiltshaw E (1983) High-dose alkylating therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft tissue sarcoma. Cancer Chemother Pharmacol 11: 69

    Google Scholar 

  148. Sullivan MP (1965) Cytoxan cystitis: Incidence and consequences. Proc Am Assoc Cancer Res 6: 63

    Google Scholar 

  149. Sutow WW (1967) Cyclophosphamide in Wilm's tumor and rhabdomyosarcoma. Cancer Chemother Rep 51: 407

    Google Scholar 

  150. Takamizawa A, Iwata T, Yamaguchi K (1976) Stereochemistry, metabolism, and antitumor activity of 4-hydroxy-isophosphamide (NSC-22714) and its stereoisomer. Cancer Treat Rep 60: 361

    Google Scholar 

  151. Talley RW, Vaitkevicius VK, Leighton GA (1965) Comparison of cyclophosphamide and 5-fluorouracil in the treatment of patients with metastatic breast cancer. Clin Pharmacol Ther 6: 740

    Google Scholar 

  152. Teufel G, Pfleiderer A (1976) Ifosfamid im Vergleich zu Endoxan bei fortgeschrittenem Ovarialkarzinomen. Geburtsh Frauenheilk 36: 274

    Google Scholar 

  153. Titscher R, Kokron O, Wrba H (1973) Fortschritte in der Behandlung des kleinzelligen Bronchialkarzinoms und des metastasierenden Seminoms durch Isophosphamid. Wien Klin Wochenschr 85: 505

    Google Scholar 

  154. Townes AS, Sowa JM, Shulman LE (1976) Controlled trial of cyclophosphamide in rheumatoid arthritis. Arthritis Rheum 19: 563

    Google Scholar 

  155. Tucker WG (1977) Ifosfamide in the treatment of lung cancer. In: Burkert H, Voigt HC (eds) Proceedings of the International Holoxan Symposium, Düsseldorf. Asta-Werke, Bielefeld, p 132

    Google Scholar 

  156. Ulrichs K, Yu MY, Duncker D, Müller-Ruchholtz W (1984) Immunsuppression by cytostatic drugs? Behring Inst Mitt 74: 239

    Google Scholar 

  157. Utracka-Hutka B, Czownicki Z (1981) Preliminary evaluation of Holoxan effectivenes in the treatment of malignant neoplasms of soft tissues and bones. Nowotwory 31: 147

    Google Scholar 

  158. Varini M, Monfardini S (1980) Natrium-2-mercaptoethanesulfonat (Mesna, Uromitexan) oral bei Ifosfamidbehandlung, präliminäre Erfahrungen. In: Burkert H, Nagel GA (eds) Beiträge zur Onkologie vol 5. Karger, Basel, p 48

    Google Scholar 

  159. Varini M, Monfardini S (1981) Oral sodium 2-mercaptoethane sulfonate mesna, uromitexan in ifosfamide therapy: preliminary report. In: Burkert H, Nagel GA (eds) New experience with the Oxazaphosphorines with special reference to the uroprotector uromitexan. Karger, Basel, p 47

    Google Scholar 

  160. Wagner T, Heydrich D, Jork T, Voelker G, Hohorst HJ (1981) Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test. J Cancer Res Clin Oncol 100: 95

    Google Scholar 

  161. Wall RL, Clausen KP (1975) Carcinoma of the urinary bladder in patients receiving cyclophosphamide. N Engl J Med 293: 271

    Google Scholar 

  162. Watson NA, Notley RG (1973) Urological complications of cyclophosphamide. Br J Urol 45: 606

    Google Scholar 

  163. Wießbach L, Kochs R (1982) Monotherapy with ifosfamide (Ifo) in the treatment of testicular tumours (non-seminomas). Proc 13th Int World Cancer Congress, Seattle, p 629, Abstr 3596

  164. Wicart L (1976) L'ifosfamide dans le traitement des tumeurs solides et de leurs metastases. Nouv Presse Med 5: 996

    Google Scholar 

  165. Wiltshaw E, Stuart-Harris R (1982) Single agent ifosfamide plus mesna for metastatic soft tissue sarcoma. Proc 13th Int Cancer Congress, Seattle, p 416, Abstr 23276

  166. Yazigi R, Wild R, Madrid J, Arraztoa J (1982) Ifosfamide in the treatment of advanced ovarian cancer. Preliminary report. Proc 13th Int Cancer Congress, Seattle, p 78, Abstr 439

  167. Yazigi R, Wild R, Madrid J, Arraztoa J (1984) Ifosfamide treatment of advanced ovarian cancer. Obstet. Gynecol. 63: 163

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Degussa Pharma Group, Medical Department, Asta-Werke, Daimlerstraße 25, D-6000, Frankfurt 1, Germany

    W. Brade & K. Herdrich

  2. Department of Hematology and Oncology, Medical Center, D-5090, Leverkusen, Germany

    S. Seeber

Authors
  1. W. Brade
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Seeber
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Herdrich
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brade, W., Seeber, S. & Herdrich, K. Comparative activity of ifosfamide and cyclophosphamide. Cancer Chemother. Pharmacol. 18 (Suppl 2), S1–S9 (1986). https://doi.org/10.1007/BF00647438

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00647438

Keywords

Search

Navigation